Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06037941 · ClinicalTrials.gov registry record · NA
Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma
A NA study of Malignant Pleural Mesothelioma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 7
- Study locations
NCT06037941 is a NA study of Malignant Pleural Mesothelioma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 20 participants, below the 87-participant average among 6 other Malignant Pleural Mesothelioma trials with a reported enrollment target (77% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT06037941, a NA study of Malignant Pleural Mesothelioma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 7
- Study locations
Study Summary
The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure how people respond to standard treatment for malignant pleural mesothelioma (MPM). The researchers will study how E-Nose breathprints change over time as people receive standard treatment for MPM. They will also look at how changes in people's E-Nose breathprints compare to changes in their standard imaging scans and in biomarkers of MPM in their blood.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST E-Nose testing
- DIAGNOSTIC_TEST Research blood
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent Only) - Commack
- Memorial Sloan Kettering Westchester (Consent Only) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Consent Only) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Consent Only) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Consent Only) - Middletown
- Memorial Sloan Kettering Bergen (Consent Only ) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-09-08 |
| Est. Completion | 2026-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06037941
The ClinicalTrials.gov registry entry for NCT06037941 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 87-participant average among 6 other Malignant Pleural Mesothelioma trials with a reported enrollment target (77% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Pleural Mesothelioma appearing as the primary indexed condition, and to 2 interventions - of which E-Nose testing is the first listed.
NCT06037941 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06037941 about?
NCT06037941 is a clinical study titled "Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma". The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure how people respond to standard treatment for malignant pleural mesothelioma (MPM). The researchers will study how E-Nose breathprints change over time as people...
What is the current status of trial NCT06037941?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2023-09-08. Estimated completion is 2026-09.
What conditions does trial NCT06037941 study?
This clinical trial studies the following conditions: Malignant Pleural Mesothelioma.
What interventions are being tested in trial NCT06037941?
The interventions under investigation include: E-Nose testing (DIAGNOSTIC_TEST), Research blood (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06037941?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06037941 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Pleural Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
ACTIVE NOT RECRUITING · Phase 1
-
Autologous Redirected RNA Meso-CIR T Cells
COMPLETED · Phase 1
-
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
COMPLETED · Phase 1
-
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.